中国新生儿与小婴儿美罗培南发育群体药代动力学-药效学:晚发型脓毒症给药建议
该研究针对中国晚发型脓毒症(LOS)新生儿,采用机会性采样策略收集美罗培南血样,构建并验证一室一级消除群体药代动力学模型,并进行蒙特卡洛模拟评估不同剂量下的靶标 attainment 概率(PTA)。共纳入78名新生儿(经后年龄27.4−46.1周),估计的体重归一化分布容积中位数(范围)为0.60(0.51−0.69)L/kg,清除率为0.16(0.04−0.51)L/h/kg。协变量分析显示经后年龄(PNA)、胎龄(GA)和当前体重(CW)是描述美罗培南药代动力学的最重要因素。模拟结果显示,对于MIC为8 mg/L的LOS,胎龄≤37周新生儿给予30 mg/kg每日3次1小时输注、胎龄>37周新生儿给予40 mg/kg每日3次3小时输注为最优方案,PTA分别为71.71%和75.08%。作者基于国内常见病原菌及其药敏模式,提出了针对中国新生儿LOS的循证给药方案。
要点
- 对中国LOS新生儿,当MIC为8 mg/L时,胎龄≤37周者美罗培南30 mg/kg每日3次1小时输注的PTA为71.71%。
- 对中国LOS新生儿,当MIC为8 mg/L时,胎龄>37周者美罗培南40 mg/kg每日3次3小时输注的PTA为75.08%。
- 群体药代动力学模型共纳入78名新生儿(经后年龄27.4−46.1周),体重归一化分布容积中位数0.60 L/kg,清除率中位数0.16 L/h/kg。
- 经后年龄、胎龄和当前体重是描述美罗培南药代动力学的最重要协变量。
适用人群与场景
- 中国晚发型脓毒症(LOS)新生儿,经后年龄27.4−46.1周,共78名。
处置流程与药物剂量
- 对于MIC为8 mg/L的LOS,胎龄≤37周新生儿给予美罗培南30 mg/kg每日3次(TID)1小时输注。
- 对于MIC为8 mg/L的LOS,胎龄>37周新生儿给予美罗培南40 mg/kg每日3次(TID)3小时输注。
研究设计与关键结果
- 研究类型:发育群体药代动力学-药效学分析,采用机会性采样策略收集美罗培南样本,进行模型构建与验证,并开展蒙特卡洛模拟评估PTA。
- 人群与样本量:78名中国新生儿,经后年龄27.4−46.1周。
- 药代动力学参数:体重归一化分布容积中位数(范围)0.60(0.51−0.69)L/kg,清除率中位数(范围)0.16(0.04−0.51)L/h/kg;数据良好拟合至一室一级消除模型。
- 协变量分析:经后年龄(PNA)、胎龄(GA)和当前体重(CW)是描述美罗培南药代动力学的最重要因素。
- 模拟结果:对于MIC为8 mg/L的LOS,胎龄≤37周新生儿给予30 mg/kg每日3次1小时输注的PTA为71.71%;胎龄>37周新生儿给予40 mg/kg每日3次3小时输注的PTA为75.08%。
证据类型、等级与局限
- 证据类型:基于群体药代动力学-药效学分析的给药建议(指南类文献)。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者基于中国新生儿LOS常见病原菌及其药敏模式,提出了美罗培南的循证给药方案:胎龄≤37周者30 mg/kg每日3次1小时输注,胎龄>37周者40 mg/kg每日3次3小时输注(针对MIC 8 mg/L)。
指南或共识出处
- 研究基于中国新生儿LOS常见病原菌及其药敏模式,提出了美罗培南给药建议,发表于Children (Basel)。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
The pharmacokinetic (PK) studies of meropenem in Chinese newborns with late-onset sepsis (LOS) are still lacking. Causative pathogens of LOS and their susceptibility patterns in China differ from the data abroad. We, therefore, conducted a developmental population pharmacokinetic−pharmacodynamic analysis in Chinese newborns with the goal to optimize meropenem dosing regimens for LOS therapy. An opportunistic sampling strategy was used to collect meropenem samples, followed by model building and validation. A Monte Carlo simulation was performed to show the probability of target attainment (PTA) for various dosages. The information from 78 newborns (postmenstrual age: 27.4−46.1 weeks) was compiled and had a good fit to a 1-compartment model that had first order elimination. The median (range) values of estimated weight−normalized volume of distribution (V)and clearance (CL) were 0.60 (0.51−0.69) L/kg and 0.16 (0.04−0.51) L/h/kg, respectively. Covariate analysis revealed that postnatal age (PNA), gestational age (GA) and current weight (CW) were the most important factors in describing meropenem PK. Simulation results showed for LOS with a minimal inhibitory concentration (MIC) of 8 mg/L, the doses of 30 mg/kg 3 times daily (TID) as a 1-h infusion for newborns with GA ≤ 37 weeks and 40 mg/kg TID as a 3-h infusion for those with GA > 37 weeks were optimal, with PTA of 71.71% and 75.08%, respectively. In conclusion, we proposed an evidence-based dosing regimen of meropenem for LOS in Chinese newborns by using the population pharmacokinetic−pharmacodynamic analysis, based on domestic common pathogens and their susceptibility patterns.
参考来源
- Wu YE, Kou C, Li X, et al. Developmental Population Pharmacokinetics-Pharmacodynamics of Meropenem in Chinese Neonates and Young Infants: Dosing Recommendations for Late-Onset Sepsis. Children (Basel). 2022. PMID: 36553441. doi:10.3390/children9121998
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。